Literature DB >> 3283038

Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin, given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice.

M Trautmann1, O Brückner, R Marre, H Hahn.   

Abstract

The therapeutic efficacy of ciprofloxacin, used alone and in combination with either ceftazidime or gentamicin, was evaluated in a model of experimental Klebsiella pneumoniae septicemia in neutropenic mice. Therapeutic results were compared to those achieved by treatment with ceftazidime or gentamicin alone, as well as their combination. Infections were induced by i.v. injection of two strains of K. pneumoniae. Therapy with i.m. antibiotics was performed in 8 h intervals for a total of 13 doses, and survival rates were recorded at the end of treatment as well as seven days later. Ciprofloxacin alone proved to be significantly more effective than ceftazidime and gentamicin, producing survival rates similar to the combination of ceftazidime plus gentamicin. Bacterial counts of spleens and blood confirmed the superior bactericidal activity of ciprofloxacin. Except for the combination of ciprofloxacin with ceftazidime, there was no apparent advantage of combinations of ciprofloxacin with the other agents compared to ciprofloxacin alone. These data suggest a high in vivo activity of ciprofloxacin in systemic infection due to K. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3283038     DOI: 10.1007/bf01646933

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

1.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

2.  Resistance to Klebsiella pneumoniae and the importance of two bacterial antigens.

Authors:  J M Cooper; D Rowley
Journal:  Aust J Exp Biol Med Sci       Date:  1982-12

Review 3.  Klebsiella bacteremia: an analysis of 100 episodes.

Authors:  M García de la Torre; J Romero-Vivas; J Martínez-Beltrán; A Guerrero; M Meseguer; E Bouza
Journal:  Rev Infect Dis       Date:  1985 Mar-Apr

4.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.

Authors:  R W Strunk; J C Gratz; R Maserati; W M Scheld
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

6.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

7.  Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.

Authors:  F M Gordin; C J Hackbarth; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin.

Authors:  D C Brittain; B E Scully; M J McElrath; R Steinman; P Labthavikul; H C Neu
Journal:  J Clin Pharmacol       Date:  1985-03       Impact factor: 3.126

9.  Gram-negative pathogens in septicaemic infections.

Authors:  L S Young; P Stevens; B Kaijser
Journal:  Scand J Infect Dis Suppl       Date:  1982

10.  Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.

Authors:  R J Jones; E A Roe; J L Gupta
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

View more
  1 in total

1.  Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.

Authors:  E Ulrich; M Trautmann; B Krause; A Bauernfeind; H Hahn
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.